AbbVie picks Singapore for a $320M production facility

Singapore has become a biopharma manufacturing hub, drawing the likes of Novartis ($NVS), GlaxoSmithKline ($GSK) and Amgen ($AMGN). Even Russia's Pharmstandard has an API facility there. Now AbbVie ($ABBV) will join the group. The maker of Humira, the best-selling drug in the world, said Wednesday that it will invest $320 million to build its first facility in Asia. The plant will be designed for both small-molecule production and biologic active ingredients for AbbVie's oncology and immunology pipeline. Story

Suggested Articles

Californian RNA biotech Arrowhead will lose its COO and R&D head from next year but is hiring a new CMO and CSO to help steady its research exec team.

The biotech began testing the small molecule in a phase 3 trial of heavily pretreated small cell lung cancer patients late last year. 

Roche is spending up to $1.4 billion to snap up a scarring-focused biotech, nabbing an FDA breakthrough-tagged therapy in the process.